Key result
In patients with asymptomatic hyperuricemia, a high-risk profile (age ≥75, BMI ≥25, and ASCVD) was associated with a greater increase in mean carotid intima-media thickness over 24 months compared to a low-risk profile.
Why the study?
Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia were largely unknown.
Observational (n=326)
Blinded-endpoint
Yes
In patients with asymptomatic hyperuricemia, higher BMI, older age, and history of ASCVD are associated with progression of carotid intima-media thickness, suggesting a higher risk of atherosclerotic progression.
Answers are grounded in this paper and cite their sources.
May aid risk stratification in asymptomatic hyperuricemia; leaves open whether BMI modification alters IMT progression.
Hyperuricemia is reportedly associated with the progression of carotid intima-media thickness (IMT), a surrogate of cardiovascular risks and events. However, factors associated with carotid IMT progression in patients with asymptomatic hyperuricemia are largely unknown. In this post-hoc analysis of the multicenter, randomized PRIZE study, we analyzed data from a total of 326 patients who underwent carotid ultrasonography in a blind manner at baseline and 24 months to evaluate carotid IMT. Mean and maximum IMT at the common carotid artery (CCA) were measured at a central core laboratory. Factors related to the absolute change in mean and maximum IMT from baseline to 24 months were explored. Overall, the adjusted mean [0.0032 (- 0.0214 to 0.0278) mm] and maximum [0.0011 (- 0.0327 to 0.0351) mm] CCA-IMT increased numerically from baseline to 24 months. Multivariable analysis identified higher body mass index, history of atherosclerotic cardiovascular disease (ASCVD), and lower mean CCA-IMT at baseline as significant factors associated with the increase in mean CCA-IMT. In addition, older age and lower mean CCA-IMT at baseline were significant factors for an increased absolute change in the maximum CCA-IMT at 24 months. The present sub-analysis of the PRIZE study showed higher body mass index, history of ASCVD, and older age as significant factors associated with CCA-IMT progression in patients with asymptomatic hyperuricemia. These factors may be considered when identifying the possible risk of atherosclerotic progression in this specific patient population of hyperuricemia.Trial registration: UMIN000012911 and UMIN000041322.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2023) conducted an observational in Asymptomatic hyperuricemia (n=326). High risk profile (age ≥ 75 years, BMI ≥ 25, and history of ASCVD) vs. Low risk profile (age < 75 years, BMI < 25, and no ASCVD) was evaluated on Absolute change in mean CCA-IMT from baseline to 24 months (MD 0.050 mm, 95% CI 0.013-0.087, p=0.008). In patients with asymptomatic hyperuricemia, a high-risk profile (age ≥75, BMI ≥25, and ASCVD) was associated with a greater increase in mean carotid intima-media thickness over 24 months compared to a low-risk profile.
Synapse has enriched 10 related papers. Consider them for comparative context: